Australian Research Data Commons (ARDC) Health Studies Australian National Data Asset (HeSANDA) Advisory Committee - of which ACTA is a member - has launched a consultation series to establish consensus between researchers involved in sharing or reusing clinical trials data on the use of a national data asset to support and improve research activities.
If you are interested in participating in the series on behalf of your organisation or network, details and EOI processes are available via the links below:
· ARDC’s Platforms program focuses on developing virtual research environments to find, collect, and analyse data, and generate FAIR (findable, accessible, interoperable and reusable) outputs. The EOI for the 2020 Platforms open call will open in early July 2020.
· The National Data Assets (NatDA) initiative will shape and contribute to creating a portfolio of national-scale data assets that support leading-edge research.
· Australian Data Partnerships program will open in early July 2020, and will establish or enhance collaborative data assets that support leading edge research, and are national in scale.
· Health Studies National Data Assets program will call for expressions of interest in Infrastructure development (Stream B) in around November 2020. HeSANDA seeks to capture the data outputs of health research studies and will fund the development of institutional infrastructure to be built to a national standard.
Visit the ARDC event page for more information.
Media Release: Australian Clinical Trials Alliance commends the Health Minister’s vision to expedite clinical trials in Australia
ACTA Trial of the Year Award 2020 guidelines and nomination forms
ACTA Year in Review: Financial Year 2018/2019
ACTA activity work plan 2019 – 2020
Report on the activities and achievements of clinical trials networks in Australia 2004 – 2014
Submission to MRFF Consultation
Submission to Medical Research Future Fund Priority Consultation
Medical Research Future Fund – clinical trial funding set to deliver significant benefits to Australian patients and the economy
ACTA Advisory Council minutes July 2017
Economic evaluation of investigator-initiated clinical trials conducted by networks
Opportunities for linking evidence development to reimbursement in Australia
Clinical Quality Registries: A national approach
How can clinical trials networks drive better translation of evidence into better quality care?
The Global Perspective: Measuring the impact of Australian-led trials & registries internationally
ACTA Summit 2016 – Opening address
ACTA Submission to the NHMRC Public Consultation on revisions to sections 3 & 5 of the National Statement
ACTA Summit 2016 – Dr Neil Soderlund
Medical Research Future Fund set to put high quality evidence at the heart of healthcare – historic moment for all Australians
ACTA Submission to the NHMRC Structural Review
ACTA Submission on the MRFF Strategy & Priorities
ACTA Submission on the National Safety and Quality Health Service Standards Version 2: Consultation Draft
ACTA Submission to the Medicare Benefits Schedule Review Taskforce
ACTA Submission to the Community Affairs Legislation Committee on the Medical Research Future Fund Bill 2015
ACTA submission on safety monitoring & reporting of clincial trials in Australia
ACTA Submission to The Independent Hospital Pricing Authority (IHPA) Teaching, Training and Research Costing Study
ACTA Submission on draft Principles for accessing and using publicly funded data for health research
WA Health joins national alliance for better evidence in healthcare
ACTA submission on revised table of standard costs for clinical trials
Report on the ACTA 2014 National Summit of Clinical Trials Networks
ACTA submission to the ACSQHC on variation in healthcare
ACTA Submission to the Select Committee on Health
ACTA Submission to the NHMRC Statement on Consumer & Community Involvement in Health & Medical Research: Public Consultation
ACTA Submission to Senate Inquiry into Australia’s Innovation System
Australian clinical trials networks shaping modern medicine: Local doctors recognised among the world’s most influential researchers of our time